Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on Non-Small Cell Lung Cancer (NSCLC)

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 191-204

  Yang, F ^a   Shi, P ^b   Xi, X ^b   Yi, S ^a   Li, H ^a   Sun, Q ^b   Sun, M ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Apoptosis; Non small cell lung cancer; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER TRANSPLANTATION; CELL ASSAY; CELL COUNT; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SOLUBILITY; SUBCUTANEOUS TISSUE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS RECOMBINANT; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; GENE THERAPY; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646875944     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:191     Document Type: Article

References (40)

1. Li L, Lu FG, Zhang SW. Twenty years change trends and forecasting analysis of China malignant mortality. Zhong hua zhong liu za zhip 1997; 19:39-42.
2. Pritti RM, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor receptor family. J Biol Chem 1996; 271:12687-12690.
3. Wiley SR, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-682.
4. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997; 137:221-229.
5. Mariani S, Krammer P. Surface expression of TRAIL/Apo2 ligand in activated mouse T and B cells. Eur J Immunol 1998; 28:1492-1498.
6. Pan G, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-113.
7. Eggert A, et al. Resistance to tumor necrosis factor-related apoptosis ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001; 61:1314-1319.
8. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersoy P. Mechnisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000; 482:193-199.
9. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001; 61:7339-7348.
10. Ashkenazi A, et al. Safety and antiumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-162.
11. Katz MH, et al. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Ann Surg Oncol 2003; 10:762-772.
12. Suzuki H, et al. Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents co-operatively induce apoptotic cell death in both sarcom and myeloma cells. Anticancer Res 2003; 23:3247-3253.
13. Lin T, et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002; 21:8020-8028.
14. Kagawa S, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61:3330-3338.
15. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165:2886-2894.
16. Kim K, Fiser MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of mormal and cancer cells. Clin Cancer Res 2000; 6:335-346.
17. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59:734-741.
18. Hernandez A, Wang QD, Schwartz SA, Evers BM. Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg 2001; 5:56-65.
19. Nguyen T, Zhang XD, Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Clin Cancer Res 2001; 7(3 Suppl):9665-9735.
20. Ibrahim SM, et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001; 23:72-79.
21. Walczak H, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-163.
22. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9:164-172.
23. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000; 60:7149-7155.
24. Nimmanapalli R, et al. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001; 61:759-763.
25. Kim MR, et al. Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett 2001; 505:179-184.
26. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59:734-741.
27. Voelkel-Johnson C, King DL, Norris JS. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin of adenoviral delivery of full-length TRAIL. Cancer Gene Ther 2002; 9:164-172.
28. Stewart AK, et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melamoma: results of phase I clinical trial. Gene Ther 1999; 6:350-363.
29. Griffith TS, Lynch DH. TRAIL: a molecule with multiple reports and control mechanisms. Curr Opin Immunol 1998; 10:559-563.
30. Pan G, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-818.
31. Sheridan JP, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-821.
32. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161:2833-2840.
33. Leverkus M, et al. Regulation of tumor necrosssis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553-559.
34. Marsters SA, et al. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by Crma. Curr Biol 1996; 6:750-752.
35. Levin AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-331.
36. Naik P, Karrim J, Hanahan D. The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev 1996; 10:2105-2116.
37. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? (Review). J Natl Cancer Inst 1997; 89:21-39.
38. Clayman GL, et al. Gene therapy for head and neck cancer, comparing the tumor suppressor gene p53 and a cell cycle regulator WAFI/CIP (p21). Arch Otolaryngol Head Neck Surg 1996; 122:489-493.
39. Sherr CJ. Cancer cell cycles (Review). Science 1996; 274:1672-1677.
40. Jarry A, et al. Position in cell cycle controls the sensitivity of colon cancer cells to nitric oxide-dependent programmed cell death. Cancer Res 2004; 64:4227-4234.